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Abstract
Cardiovascular system involvement is a frequent complication of autoimmune diseases (AD) 
such as systemic lupus erythematosus, scleroderma, rheumatoid arthritis, spondyloarthropaties 
or psoriatic arthritis. The most common forms of such involvement are pericarditis, myocar-
ditis, accelerated atherosclerosis resulting in myocardial infarction or stroke, arrhythmias, 
conduction abnormalities or congestive heart failure. Some of these manifestations may be 
dramatic in their course and ultimately fatal. The treatment of AD may further affect the car-
diovascular system and result in a lower quality of life, higher mortality and increased cost of 
healthcare. The aim of this review is to discuss possible cardiac complications of various AD 
and the related treatment of these diseases. (Cardiol J 2013; 20, 6: 569–576)
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Introduction
In developed countries approximately 25% of 
the general population suffers from some form of 
autoimmune disorders [1]. Autoimmune diseases 
(AD) are characterized by a primary dysfunction of 
the immune system with increased level of auto-
antibodies, inflammatory and mediatory cells resul-
ting in chronic inflammation of connective tissue 
[2]. The risk factors influencing the development 
of AD include: advancing age, gender, genetics, 
environmental insults, and infections [3]. Women 
tend to be stricken more often with rheumatoid 
arthritis, systemic lupus erythematosus (SLE) 
and scleroderma (SCL), while men tend to suffer 
from ankylosing spondylitis and certain types of 
vasculitis. 
AD can be subdivided into organ specific and 
non-organ-specific [2]. The examples of organ 
specific AD include type 1 diabetes mellitus, which 
results from pancreatic insufficiency following the 
annihilation of beta cells through the invasion of 
T-cells, leading to insulin deficiency; Hashimoto’s 
thyroiditis and Graves’ disease affecting the thyroid 
gland but resulting in multi-system effect. Diffuse 
non-organ specific autoimmune diseases, such as 
SLE or SCL, tend to have a multi system involve-
ment, including the cardiovascular (CV) system. 
Autoimmune diseases and  
the cardiovascular system
Pericarditis is the most common CV com-
plication of AD and is considered to be immune-
-mediated, although co-existing infection may play 
a role in some cases [1]. It is a frequent symptom 
in SCL (50% of patients), SLE and rheumatoid 
arthritis (30% each), and its extension generally 
reflects the activity of the systemic involvement of 
AD [2]. Asymptomatic pericardial effusion and/or 
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pericarditis may be the primary and sole manife-
stations of an underlying autoimmune process. 
Arrhythmias or conduction disorders are quite 
frequent in AD. They tend to be caused by an 
infiltration of inflammatory cells with ensuing fi-
brosis of the conductive system and myocardium. 
Inflammatory infiltrates are usually observed in 
SCL, systemic lupus erythematosus, rheumatoid 
arthritis, and seldom in polymyositis, dermatomyo-
sitis and mixed connective tissue disease. Auto-
immune mediated inflammatory process may also 
affect coronary arteries and lead towards ischemic 
heart disease or acute coronary syndromes. Non-
-infective endocarditis with primary involvement of 
the left heart valves is observed in systemic lupus 
erythematosus. Pulmonary hypertension, develo-
ping during the course of AD is an example of an 
indirect effect on cardiac function. Autoimmune 
inflammatory processes can have disastrous effects 
on major vessels, causing aneurysms, arterial and 
venous thrombi and various forms of embolization. 
These can develop into emergent and potentially 
fatal scenarios. It would be worthy to note that each 
of ADs directly or indirectly affects the CV system 
with varying severity [2–4]. 
SLE is an inflammatory disease of the con-
nective tissue, affecting approximately 0.1% of 
the general population, with the female-to-male 
ratio 6–10:1. Pericarditis manifests in just a bit 
over 50% of SLE patients, however they may re-
main asymptomatic. In certain cases pericarditis 
may precede clinical signs of SLE or exacerbate 
the underlying disease. On CV imaging, small 
pericardial effusions and thickening of pericardial 
plaques may be observed in SLE patients. Clinically 
urgent pericarditis occurs in 30% of patients, with 
substantial fluid accumulation resulting in cardiac 
tamponade [5, 6]. In the latest clinical evaluations, 
cardiac tamponade was found in 22% of patients, 
whose management required high-dose cortico-
steroids and in half these cases — a pericardial 
window [7]. Antiphospholipid antibodies, detected 
in approximately 30–50% of SLE patients, are the 
main risk factor for CV complications [6]. These 
antibodies cause complement activation and 
deposition of immune complexes in tissues and 
may affect the conductive system of the heart. 
Non-infective verrucous vegetations found on 
valves, first described in 1924 as the Libman-Sachs 
endocarditis, are one of the most characteristic 
symptoms of SLE. In 63% of cases the mitral valve 
is involved, however aortic valve or multivalvular 
involvement is relatively common. Libman-Sachs 
endocarditis occurs in 50% of patients with SLE [8]. 
It is usually mild but in approximately 20% of cases 
have a severe progression to valvular dysfunction 
requiring surgical intervention [9–15]. Over the na-
tural course of SLE, several inflammatory changes 
take place within the endothelium (accumulation 
of inflammatory cells, thickening of intima-media, 
formation of plaques), leading to premature and 
accelerated atherosclerosis, with increased risk of 
coronary heart disease and/or stroke. The risk of 
acute coronary syndromes is significantly increa-
sed, when compared to the general population, in 
each age group of patients with concomitant SLE 
and antiphospholipid syndrome, but is particularly 
greater in young women whose risk is increased 
50-fold. In the John Hopkins SLE Cohort Study, 
coronary artery disease occurred in over 8% of 
the studied patients and was responsible for 30% 
of deaths in the 3-year follow-up. In the Toronto 
Cohort Study 11% of SLE patients developed co-
ronary artery disease due to the vascular changes. 
Pulmonary arterial hypertension can occur as pa-
tients develop interstitial lung disease or intimal 
proliferation of pulmonary arteries [16]. Within 
this patient group, the CV risk is significant and 
associated with a worse prognosis. Neonatal lupus, 
a congenital form of SLE, is a passively transfer-
red autoimmune disease. It concerns 1.6–2% of 
neonates born to mothers with SLE. It may be 
diagnosed in young infants causing complete he-
art block (detected by fetal echocardiography or 
magnetocardiography at about 20 weeks gestation). 
Fortunately, neonatal lupus typically resolves by 
the age of 6-months [2, 17].
In the 8-year follow-up multi-centre study 
(Atherosclerotic Vascular Events Cohort of SLE), 
the prevalence of atherosclerotic vascular events 
was found to vary between 8–13% within SLE 
patients, with a peak incidence 8 years after diag-
nosis. In the Pittsburgh Cohort, the CV risk among 
women with SLE was found to be approximately 
7%. Prolong duration of SLE and extended use of 
corticosteroid were the main risk factors for the 
development of CV events [18]. 
Antiphospholipid syndrome, also known as 
Hughes syndrome, is an inflammatory disorder 
that presents with antiphospholipid antibodies 
causing arterial and venous thrombosis. Pulmonary 
hypertension is relatively common, occurring in 
approximately 70% of patients with antiphospho-
lipid antibodies [19]. Antiphospholipid antibodies 
cause an activation of complement, followed by 
deposit formation of immune complexes in tissues. 
These patients may suffer from angina pectoris 
and, in some (8%) advanced cases, myocardial 
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infarction (MI). Additionally, there is an increased 
risk of re-occlusion following coronary angioplasty 
or coronary artery bypass grafting [20–23]. 
Valvular (mitral and aortic) regurgitation 
(12%), secondary to their thickening (30%) or 
destruction, is usually a mild form of valvular 
impairment, but in 4–6% of patients it progresses 
to severe valvular defects necessitating surgical 
intervention. Most of the valvular involvement 
is clinically silent, some of patients, may have 
severe thromboembolic events, including stroke 
[24–26].
SCL is a disease which causes the fibrosis 
of the skin and internal organs, affecting 70,000 
Americans. Female-to-male ratio is 7–10:1 [2]. CV 
complications in SCL patients include: pericarditis, 
cardiac arrhythmias, congestive heart failure (HF) 
and pulmonary hypertension — the main cause of 
death in SCL patients. In large cohort studies on 
SCL, the CV system involvement was responsible 
for up to 36% of all deaths, while cardiopulmonary 
deaths accounted for 70% of the mortality [27]. 
Symptomatic pericarditis occurs in approximately 
20% of SCL patients, with evidence of pericardial 
involvement found in 80% of autopsy cases [28]. 
Inflammation and autoimmunity stimulate fibro-
blasts activation, myofibroblasts recruitment, and 
production of collagen leading to fibrosis. Progres-
sion of myocardial fibrosis in SCL results in the de-
velopment of cardiomyopathy followed by diastolic 
and systolic HF with significantly reduced left ven-
tricular ejection fraction [29]. Recent studies have 
revealed myocardial fibrosis in 37% of SCL autopsy 
cases. Fibrosis leads to reduced coronary blood 
flow resulting in myocardial ischemia and may 
even precipitate MI. In the absence of significant 
coronary narrowing, a reduction in coronary blood 
flow reserve is observed in 55% of asymptomatic 
patients. This suggests that myocardial involve-
ment is due to the impairment of microcirculation 
and is associated with structural abnormalities of 
small coronary vessels [30]. Coronary angiograp-
hy revealed tortuosity (50%), calcification (33%), 
stenosis (20%), ectasia and slow flow (20%), and 
spasm (< 10%) in SCL patients [31]. Pulmonary 
hypertension has a yearly incidence of 6 in 1000 
SCL patients as a result of pulmonary vascular 
obliteration, interstitial fibrosis of pulmonary tissue 
or left ventricular HF, and less frequently by pulmo-
nary embolization. Lung disease is found in 80% of 
SCL patients. A recent meta-analysis of more than 
3.5 thousands patients showed that SCL associated 
pulmonary arterial hypertension (PAH) is particu-
larly aggressive. Untreated PAH is associated with 
a median survival of 1 year following its diagnosis 
in SCL patients. PAH remains the main cause of 
death among SCL patients [31]. The 3-year mor-
tality of SCL patients with PAH varies between 
36% and 53% with different reports. Mortality is 
significantly higher (61–72%) in SCL patients with 
pulmonary hypertension secondary to interstitial 
lung disease [32, 33]. 
Echocardiography reveals left ventricular 
systolic dysfunction in about 30% of patients, and 
thickening of the aortic and mitral valve leaflets 
in 12% and 8%, respectively [2, 34, 35]. A quarter 
of patients with progressive SCL have developed 
antibodies to cardiac conducting tissue. ECG 
studies show that arrhythmias and conduction 
abnormalities are quite frequent in SCL. These 
are usually incomplete right bundle branch block 
(41%), benign supraventricular arrhythmias, tran-
sient atrial fibrillation, atrial flutter, first degree 
atrioventricular block, and nodal rhythms (each 
10%). These ECG abnormalities are likely to be 
transient and result from fibrosis of the myo-
cardium and conductive system. In 6–10% of 
SCL patients, sudden cardiac death secondary to 
ventricular arrhythmia is reported. Studies found 
that 75% of SCL patients have a normal resting 
ECG and 24-h Holter monitoring [34]. Other cli-
nical studies revealed the presence of ventricular 
arrhythmia in a form of frequent single premature 
ventricular beats, as bigeminy, trigeminy or pairs 
in 67% of SCL patients. More serious ventricular 
arrhythmias such as non-sustained ventricular 
tachycardia is observed in 7–13% of SCL patients. 
Supraventricular arrhythmias were less frequent in 
SCL — atrial fibrillation/flutter or supraventricular 
paroxysmal tachycardia were found in 20–30% of 
patients. Conduction disturbances were diagnosed 
in 25–75% of SCL patients. Sudden cardiac deaths 
were reported in 5–21% of individuals, usually in 
patients with skeletal muscle involvement. One 
effective treatment is cardiac ablation for drug-into-
lerant and drug-resistant arrhythmias; it, however, 
should be considered as an alternative treatment. 
Life-threatening ventricular arrhythmias require 
an implantable cardioverter defibrillator, whereas 
advanced conduction disorders need to be managed 
with a pacemaker implantation [27]. The question 
must be asked whether it would be warranted to 
implant a cardioverter-defibrillator device in SCL 
patients, as a primary prevention.
Rheumatoid arthritis (RA) is an inflammatory 
disease with distinctive joint malformations affec-
ting about 1–2% of the general population. Peak 
incidence occurs in the fourth and fifth decade of 
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life, 3 times more often in women. Patients with 
RA have a significantly increased risk of developing 
HF (34%) compared to the general population. In 
particular, this trend is strongly marked in women, 
and is constantly higher in the long-term follow-up 
suggesting that prolonged exposure to inflamma-
tory agents has no impact on the development of 
HF [36–38]. Similarly, there is a high prevalence of 
coronary heart disease, with 43% higher risk for pa-
tients with positive rheumatoid factor and as much 
as 2.5-fold increased risk for patients without the 
presence of rheumatoid factor. Effects of chronic 
inflammation, such as endothelial dysfunction and 
dyslipidemia, increase risk of CV mortality. Silent 
course of angina pectoris with frequent complica-
tion of sudden cardiac death is characteristic for 
RA. Inflammatory changes, especially in the left 
anterior descending and left circumflex arteries, 
are found at autopsies [39–43]. Pericarditis is 
a common symptom of heart involvement in RA and 
it is present in 75% of patients [2]. Constrictive 
pericarditis may occur in few percent. Pulmonary 
hypertension is rare and usually secondary to 
intestinal lung disease. Pathologic examinations 
revealed inflammatory pulmonary vasculitis, ple-
xiform vasculopathy with intimal hyperplasia and 
smooth muscle hypertrophy [44]. Pulmonary hy-
pertension may also originate from chronic venous 
thromboembolic disease, especially in patients 
with coexisting SCL. Some clinical studies repor-
ted an increase in the carotid artery intima-media 
thickness in RA patients compared to the general 
population [3]. Certain RA patients may develop 
valvular dysfunction [45]. CV complications affect 
53% of RA patients [46, 47]. 
In a retrospective population-based cohort 
from the Rochester Epidemiology Project, the 
10-year CV risk in RA patients was found to be 
comparable to that of healthy individuals who were 
on the average 10 years older [48]. 
Patients suffering from polymyositis and der-
matomyositis, diseases involving the skin and 
muscles which have co-existing CV disease, are 
deemed to have a poor prognosis. It is estimated 
that up to 20% of patients with polymyositis die 
from cardiac disease. The average risk of post MI 
mortality in polymyositis and dermatomyositis 
is 16-fold increased; men 9-fold, women up to 
32-fold. Congestive HF (up to 45%), angina pectoris 
(44%), MI, Prinzmetal angina and pericarditis (10% 
respectively) are the most common manifestation 
of cardiac involvement in these patients. The fre-
quency of these CV complications varies depending 
on the population selected and diagnostic methods 
used. Another reported CV complications are 
arrhythmias and conductive abnormalities, which 
include supraventricular or ventricular tachycar-
dia, atrioventricular blocks, bundle branch blocks, 
nonspecific ST-T changes and abnormal Q waves 
occurring in 32% of patients [49]. Lymphocyte 
infiltration throughout the sinoatrial node is rare, 
however when it occurs, it results in a complete 
heart block requiring a pacemaker implantation. 
Extensive deposits of inflammatory cells (prima-
rily T lymphocytes and macrophages) followed by 
degeneration of cardiac myocytes and secondary 
restrictive cardiomyopathy. As a result, severe 
congestive HF with significantly reduced left ven-
tricular ejection fraction is observed. Interstitial 
lung disease is also found in 5–30% of patients and 
leads to right ventricular HF [49].
The Quebec cohort study recruited 607 pa-
tients with dermatomyositis and polymyositis 
showed the risk of MI equal to 5.3/1000 person-
-years. Higher incidence of MI in patients with 
dermatomyositis and polymyositis comparing to 
the general population was observed in all demo-
graphic groups except men younger than 65 years. 
In this cohort, the rate of stroke was 5.1/1000 
person-years, twice as high as in healthy subjects 
(3.1/1000 person-years) and similar to recorded in 
RA patients. 
In the case-control study of the Healthcare 
Cost and Utilization Project, data from over 50,000 
hospitalizations of patients with dermatomyositis 
(20% of US hospitals) were analyzed. For dermato-
myositis patients, the rate of death and CV diseases 
was 2-fold higher than in age- and gender-matched 
patients without dermatomyositis. Congestive 
HF was one of the most frequent causes of death 
in these patients. This study also found that the 
prevalence of hypertension and diabetes mellitus 
among dermatomyositis patients was significantly 
higher than in the general population (62% and 
29% compared with 9% and 4%, respectively). 
Similar findings were observed in patients with 
dermatomyositis or polymyositis regarding any 
cerebrovascular accident [50]. 
Spondyloarthropaties are inflammatory dise-
ases of the vertebral column. The most common 
of these — ankylosing spondylitis (AS) is diagno-
sed in approximately 1.5% of the population, with 
2–3:1 male-to-female ratio, affecting younger male 
population. The most common CV complications 
found in patients with AS are: aortic regurgitation 
(up to 50%), inflammation of the ascending aorta, 
atrio-ventricular blocks, bundle branch blocks 
and pericarditis. Presence of the HLA-B27 gene 
www.cardiologyjournal.org 573
Marta Jastrzębska et al.,  Autoimmune diseases and the cardiovascular system
predisposes individuals to proximal aortitis, dia-
stolic dysfunction and conduction abnormalities 
[51]. Aortic root disease is reported in 100% of 
autopsies and in over 80% of transoesophageal 
echocardiographies. Twenty percent of patients 
with ascending aorta disease may have either 
congestive HF, experienced stroke or undergone 
valve replacement surgery [52]. 
Psoriatic arthritis affects about 0.5% of the 
general population. The inflammation of the ascen-
ding aorta with secondary aortic valve involvement 
may develop as a result of psoriatic arthritis. 
This is, however, an extremely rare complication. 
CV symptoms are significantly more frequent 
in patients with reactive arthritis. Pericarditis, 
myocarditis, inflammation of initial segment of 
the ascending aorta with secondary aortic valve 
regurgitation, and nonspecific ST-T changes or 
conduction abnormalities are diagnosed [53].
Summary of the CV complications in autoim-
mune diseases is shown in Table 1.
Treatment of autoimmune diseases  
and cardiovascular system 
In spite of the unfavorable influence of autoim-
mune diseases, AD treatment has also a significant 
impact on the CV system. The pharmaceutical 
treatment of autoimmune inflammatory diseases 
takes a toll on the CV system, creating a broad 
array of side effects. The most common drugs used 
in AD pharmacotherapy are non-steroidal anti-
-inflammatory drugs (NSAIDs), glucocorticoids, 
and so-called disease-modifying antirheumatic 
drugs (DMARDs) like methotrexate, sulfasalazine 
or chloroquine. Cyclophosphamide, cyclosporine, 
and biological treatment are also used.
Glucocorticoids are associated with hyperten-
sion (62%), diabetes (18%), dyslipidemia (66%) or 
thromboembolic complications. They alter kidney 
function inducing fluid and electrolyte disorders, 
resulting in congestive HF and hypertension [54, 
55]. Glucocorticoids are generally considered to 
increase the CV risk. Although, the case-control 
nationwide study has not confirmed this finding 
[50]. Contrary, results from the QUEST-RA study 
showed that glucocorticoids use is accompanied 
by a small decrease in risk of all CV events [56]. 
Recent studies in SLE and RA have suggested that 
corticosteroids have a potential to reduce CV risk 
probably by lowering the autoimmune activity and 
the severity of inflammation [57].
NSAIDs therapy increases the risk of MI, 
cerebrovascular accident, congestive HF and sy-
stemic hypertension [58]. NSAIDs are especially Ta
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dangerous in the elderly, as they may exacerbate 
pre-existing HF due to renal dysfunction [59, 60]. 
The cyclooxygenase-2 (COX-2) inhibitors may 
create a pro-thrombotic/coagulation imbalance on 
the endothelial surface, with thrombus formation 
and potentially fatal embolization. Two large meta-
-analyses based on over 90 clinical trials showed 
that NSAIDs increase blood pressure, with higher 
elevations in hypertensive patients. This drug-
-induced elevation of blood pressure is associated 
with a reduction in blood concentrations of prosta-
glandins and renin. Among the NSAIDs reviewed, 
piroxicam induces the highest increase in blood 
pressure, whereas aspirin and flurbiprofen evoke 
a lower increase in overall blood pressure. NSAIDs 
interfere with the anti-hypertensive effects of 
several classes of CV drugs, including: diuretics, 
angiotensin-converting enzyme inhibitors and 
beta-blockers. Sustained use of non-selective 
NSAIDs and selective COX-2 inhibitors results in 
an extremely increased hazard ratio for ischemic 
stroke, 1.7 and 4.5, respectively. Furthermore, 
NSAIDs therapy is associated with sodium and 
water retention, with double the hospitalizations 
due to congestive HF [58–60].
Patients being treated with sulfasalazine and 
leflunomid may develop pericarditis and hyper-
tension, respectively. Chloroquine an antimalarial 
drug, which has shown a great benefit in the mana-
gement of ADs has been associated with widening 
of the QRS complex, QT interval prolongation, 
T wave changes and in rare cases complete he-
art block, necessitating pacemaker implantation 
[61–63]. Cardiomyopathy and ensuing congestive 
HF resulting from long-term chloroquine therapy 
have also been reported, albeit rarely [64–66]. 
In the case-control study, DMARDs (especially 
azathioprine) correlate inversely with the CV 
events in dermatomyositis and polymyositis. Hy-
droxychloroquine improved lipid profiles in SLE 
patients, however this study failed to prove its 
beneficial effect on the clinical events form the CV 
system [50]. A huge QUEST-RA study (2005–2006) 
recruiting over 4000 patients from 15 countries 
proved that one year treatment with methotrexate 
was associated with 15%, 18%, and 11% decreases 
of risk for all CV events, MI, and stroke, respecti-
vely [56]. Methotrexate may cause pericarditis or 
pericardial effusions, and lead to pulmonary fibrosis 
and congestive HF. Methotrexate may increase the 
risk of hypotension, diabetes and thromboembolic 
events (arterial thrombosis, cerebral thrombosis, 
deep vein thrombosis, retinal vein thrombosis, 
pulmonary embolization). How ever, methotrexate 
has been of some benefit to the CV system as it has 
been reported to reduce atherosclerotic lesions in 
coronary arteries [67]. It also can be used as adjun-
ctive therapy for asthma to reduce inflammation.
Infliximab increases the frequency of arrhyth-
mias, hypertension and HF, and in rare cases may 
cause episodes of hypotension. However, the large 
population QUEST-RA study revealed lowered risk 
for all CV events in patients with a long history of 
TNF-alpha blockers treatment [56].
Etanercept, an immunosuppressive agent with 
an extremely long half-life of 102 ± 30 h, is used 
to treat rheumatoid arthritis. Etanercept has many 
side effects from increased risk of coronary artery 
disease, MI, chronic HF, deep vein thrombosis and 
hypertension. Fortunately, these side effects are 
relatively rare and observed in only 1.5% of patients 
receiving this treatment [68].
Cyclosporine inhibits the cellular and humoral 
immune response by modifying inflammatory rea-
ctions by its influence over the TH cell activation, 
indirectly inhibiting the production of antibodies 
and macrophage activation. Patients treated with 
cyclosporine may experience hypertension, hyper-
lipidemia, chest pain or cardiac arrhythmias. The 
most severe complication of cyclosporine therapy 
is renal failure resulting in hypertension, fluid and 
electrolytes imbalance (hyperkalemia, hypomag-
nesemia) and imminent congestive HF [69, 70].
Anakinra, a human interleukin-1 receptor 
antagonist, was first used in to treat autoimmune 
disease in 2001. According to more recent reports, 
it also helps reduce myocardial ischemia in acute 
coronary syndromes. The exact mechanism of 
action is not fully known and requires further 
evaluation [71].
Summary of the CV side effects of the drugs 
used in AD therapy is shown in Table 2.
Implantable cardioverter-defibrillators have 
proven themselves in preventing sudden cardiac 
death, in cardiac patients, however there is lacking 
data on their use in patients who manifest life 
threatening arrhythmias as a result of autoimmune 
disease and therefore a further investigation is 
required.
Conclusions
Multisystem involvement is the hallmark of 
AD, and the CV system is a frequent target of the 
most common systemic autoimmune diseases. In 
the last several decades, the increased prevalence 
of CV complications in patients with AD has been 
observed. CV manifestations range from mild 
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to severe, even being the initial presentation of 
AD. Cardiologists should remain vigilant to for 
underlying diseases. Since silent CV involvement 
is common, it is rarely recognized.
Both autoimmune diseases and their manage-
ment have a significant impact on the CV system, 
which results in decreased quality of life, higher 
mortality and increased cost of healthcare. Im-
proving the quality of life, preventing CV adverse 
events, decreasing hospitalizations and mortality, 
all-the-while minimizing pharmacological side ef-
fects is the present goal of this multidisciplinary 
management of autoimmune disease.
Acknowledgements
This work is a part of the project ‘Predicting 
adverse clinical outcomes in patients with implan-
ted defibrillating devices’, which was supported 
by the Foundation for Polish Science — TEAM 
program co-financed by the European Union within 
the European Regional Development Fund. 
Conflict of interest: none declared
References
 1.  Bonow RO, Mann DL, Zipes DP et al. Braunwald’s heart disease: 
A textbook of cardiovascular medicine. Saunders, Philadelphia 2011: 
2107–2116. 
 2.  Knockaert DC. Cardiac involvement in systemic inflammatory dise-
ases. Eur Heart J, 2007; 28: 1797–1804. 
 3.  Villa-Forte A, Mandell BF. Cardiovascular disorders and rheumatic 
disease. Rev Esp Cardiol, 2011; 64: 809–817.
 4.  Kitas G, Banks MJ, Bacon PB. Cardiac involvement in rheumatoid 
disease. Clin Med, 2001; 1: 18–21.
 5.  Crozier IG, Li E, Milne MJ, Nicholls MG. Cardiac involvement in 
systemic lupus erythematosus detected by echocardiography. Am J 
Cardiol, 1990; 65: 1145–1148.
 6.  Doria A, Iaccarino L, Sarzi-Puttini P, Atzeni F, Turriel M, Petri M. 
Cardiac involvement in systemic lupus erythematosus. Lupus, 2005; 
14: 683–686.
 7.  Rosenbaum E, Krebs E, Cohen M et al. The spectrum of clinical 
manifestations, outcome and treatment of pericardial tamponade in 
patients with systemic lupus erythematosus: a retrospective study and 
literature review. Lupus, 2009; 18: 608–612.
 8.  Nihoyannopoulos P, Gomez PM, Joshi J et al. Cardiac abnormalities in 
systemic lupus erythematosus. Association with raised anticardiolipin 
antibodies. Circulation, 1990; 82: 369–375.
 9.  Fernández-Dueñas J, López-Granados A. Severe mitral regurgitation 
in libman-sacks endocarditis conservative surgery. Rev Esp Cardiol, 
2005; 58: 1118–1120.
 10.  Moaref AR, Afifi S, Rezajan S, Rezajan GR. Isolated tricuspid valve 
libman-sacks endocarditis and valvular stenosis: Unusual manifesta-
tions of systemic lupus erythematosus. J Am Society Echocardiog, 
2010; 23: 341–345.
 11.  Moder KG, Miller TD, Tazelaar HD. Cardiac involvement in systemic 
lupus erythematosus. Mayo Clin Proc, 1999; 74: 275–284.
 12.  Moyssakis I, Tekonidou M, Vassilios V et al. Libman-Sacks endocar-
ditis in systemic lupus erythematosus: Prevalence, associations, and 
evolution. Am J Med, 2007; 120: 636–642. 
 13.  Van der Laan-Baalbergen NE, Mollema SA, Kritikos H. Heart failure 
as presenting manifestation of cardiac involvement in systemic lupus 
erythematosus. Neth J Med, 2009; 67: 295–301.
 14.  Ohara N, Myiata T, Kurata A, Oshiro H, Sato O, Shigematsu H. Ten 
years’ experience of aortic aneurysm associated with sys temic lupus 
erythematosus. Eur J Vasc Endovasc Surg, 2000; 19: 288–293.
 15.  Roldan CA, Shively BK, Crawford MH. An echocardiographic study of 
valvular heart disease associated with systemic lupus erythematosus. 
N Engl J Med, 1996; 335: 1424–1430.
 16.  Johnson SR, Gladman DD, Urowitz MB, Ibanez D, Granton JT. 
Pulmonary hypertension in systemic lupus erythematosus. 
Lupus, 2004; 13: 506–509.
 17.  Jordan JM, Valenstein P, Kredich DW. Systemic lupus erythematosus 
with Libman-Sachs Endocarditis in a 9-month-old infant with neonatal 
lupus erythematosus and congenital heart block, Pediatrics,1989; 84: 
574–578.
 18.  Urowitz MB, Gladman D, Ibanez D. Atherosclerotic vascular events 
in a multinational inception cohort of systemic lupus erythematosus, 
arthritis. Care Res, 2010; 62: 881–887.
Table 2. Side effect of drugs used in autoimmune diseases of the cardiovascular system.
Drug Side effects from the cardiovascular system
Glicocorticosteroids Arterial hypertension, diabetes, thromboembolic complications, renal impairment,  
heart failure
Nonsteroidal anti- 
inflammatory drugs
Edema, arterial hypertension, worsening heart failure, acute coronary events
Sulfasalazine Pericarditis
Leflunomid Arterial hypertension
Chloroquine Arterial hypotension, changes in the ECG: QRS prolongation, QT prolongation,  
T wave changes, cardiomyopathy, III degree atrioventricular block, heart failure,  
ventricular arrhythmias
Infliximab Arrhythmias, arterial hypertension, heart failure aggravation, arterial hypotension
Etanercept Coronary artery disease, myocardial infarction, heart failure, thrombosis, arterial  
hypertension
Cyclosporine Chest pain, irregular heartbeat, kidney failure, arterial hypertension, heart failure
Metotrexate Pericardial effusion, pulmonary fibrosis, asthma, pulmonary hypertension,  
heart failure, diabetes
Beneficial effect of reducing atherosclerotic lesions in coronary arteries
Anakinra Beneficial effect of reducing the area of ischemia in acute coronary syndromes
576 www.cardiologyjournal.org
Cardiology Journal 2013, Vol. 20, No. 6
 19.  Asherson RA, Cervera R. Antiphospholipid antibodies and the he-
art. Lessons and pitfalls for the cardiologist. Circulation, 1991; 84: 
920–923.
 20.  Bili A, Moss AF, Francis CW et al. Anticardiolipin antibodies and reccu-
rent coronary events: a prospective study of 1150 patients. Circulation, 
2000; 102: 1258–1263.
 21.  Greco T, Conti-Kelly AM, Doyle R et al. Newer antiphospholipid 
antibodies predict adverse outcomes in patients with acute coronary 
syndrome. Am J Clin Pathol, 2009; 132: 613–620. 
 22.  Gurlek A, Ozdol C, Pamir G et al. Association between anticardiolipin 
antibodies and recurrent cardiac events in patients with acute coronary 
syndrome. Int Heart J, 2005; 46: 631–638.
 23.  Vaarala O, Mänttäri M, Manninen V et al. Anticardiolipin antibodies 
and risk of myocardial infarction in a prospective cohort of middle-aged 
men. Circulation, 1995; 91: 23–27.
 24.  Koniari I, Siminelaki SN, Baikoussis GN et al. Antiphospholipid 
syndrome; its implication in cardiovascular diseases: A review. 
J Cardiothorac Surg, 2010; 5: 101.
 25.  Turiel M, Muzzupappa S, Gottardi B. Evaluation of cardiac abnormalities 
and embolic sources in primary antiphospholipid syndrome by transesop-
hageal echocardiography. Lupus, 2000;9:406–412.
 26.  Hojnik M, George J, Ziporen L, Shoenfeld Y. Heart valve involvement 
(Libman-Sacks endocarditis) in the antiphospholipid syndrome. Circu-
lation, 1996;92:1579–1587.
 27.  Plastiras SC, Toumanidis ST. Systemic sclerosis: The heart of the 
matter, hellenic. J Cardiol 2012; 53: 287–300.
 28.  Byers RJ, Marshall DAS, Freemont AJ. Pericardial involvement in 
systemic sclerosis. Ann Rheum Dis, 1997; 56: 393–394.
 29.  Nakajima K, Kawano M, Hasegawa M et al. Myocardial damages in 
systemic sclerosis detected by gated myocardial perfusion SPECT 
sympathetic imaging. Circ J, 2006; 70: 1481–1487.
 30.  Vacca A, Siotto P, Cauli A et al. Absence of epicardial coronary stenosis 
in patients with systemic sclerosis and severe impairment of coronary 
flow reserve. Ann Rheum Dis, 2006; 65: 274–275.
 31.  York M, Farber HW. Pulmonary hypertension: Screening and evalua-
tion in scleroderma. Curr Opin Rheumatol, 2011; 23: 536–544.
 32.  Chang B, Schachna L, White B, Wigley FM, Wise RA. Natural history 
of mildmoderate pulmonary hypertension and the risk factors for severe 
pulmonary hypertension in scleroderma. J Rheumatol, 2006; 33: 269.
 33.  Mathai SC, Hummers LK, Champion H. Survival in pulmonary 
hypertension associated with the scleroderma spectrum of diseases 
impact of interstitial lung disease. Arthritis Rheum, 2009; 60: 569–577.
 34.  Kahan A, Coghlan G, McLaughlin V. Cardiac complications of systemic 
sclerosis. Rheumatolog, 2009; 48: 45–48.
 35.  Moyssakis I, Gialafos E, Vassiliou V et al. Aortic stiffness in systemic 
sclerosis is increased independently of the extent of skin involvement. 
Rheumatology, 2005; 44: 251–254.
 36.  Nomeir AM, Turner RA, Watts LE. Cardiac involvement in rheumatoid 
arthritis: follow-up study. Arthritis Rheum, 1979; 22: 561–564.
 37.  Nicola P, Crowson CS, Maradit-Kremers H et al. Contribution of con-
gestive heart failure and ischemic heart disease to excess mortality in 
rheumatoid arthritis. Arthritis Rheum, 2006; 54: 60–67.
 38.  Udayakumar N, Venkatesan S, Rajendiran C. Diastolic function ab-
normalities in rheumatoid arthritis: relation with duration of disease. 
Singapore Med J, 2007; 48: 537.
 39.  Chung CP, Oeser A, Raggi P et al. Increased coronary-artery atheroscle-
rosis in rheumatoid arthritis. Arthritis Rheum, 2005; 52: 3045–3053.
 40.  Francis ML, Varghese JJ, Mathew JM et al. Outcomes in patients with 
rheumatoid arthritis and myocardial infarction. Am J Med, 2010; 123: 
922–928.
 41.  Gonzalez-Juanatey C, Llorca J, Testa A, Revuelta J, Garcia-Porrua C, 
Gonzalez-Gay MA. Increased prevalence of severe subclinical athe-
rosclerotic findings in long-term treated rheumatoid arthritis patients 
without clinically evident atherosclerotic disease. Medicine, 2003; 
82: 407–413.
 42.  Salmon JE, Roman MJ. Subclinical atherosclerosis in rheumatoid art-
hritis and systemic lupus erythematosus. Am J Med, 2008; 121: 53–58.
 43.  Maradit-Kremers H, Crowson CS, Nicola P. Increased unrecognized 
coronary heart disease and sudden deaths in rheumatoid arthritis 
a population-based cohort study. Arthritis Rheum, 2005; 52: 402–411.
 44.  Seyfeli E, Guler H, Akoglu S et al. Right ventricular diastolic abnorma-
lities in rheumatoid arthritis and its relationship with left ventricular 
and pulmonary involvement. Int J Cardiovasc Imag, 2006; 22: 745–754.
 45.  Roldan CA, DeLong C, Qualls C, Crawford MH. Characterization of 
valvular heart disease in rheumatoid arthritis by transesophageal echo-
cardiography and clinical correlates. Am J Cardiol, 2007; 100: 496–502.
 46.  Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F. Metho-
trexate and mortality in patients with rheumatoid arthritis: 
a prospective study. Lancet, 2002; 359: 1173–1177.
 47.  Voskuyl AE. The heart and cardiovascular manifestations in rheuma-
toid arthritis. Rheumatology, 2006; 45: 4–7.
 48.  Kremers HM, Crowson CS, Therneau TM et al. High ten-year risk 
of cardiovascular disease in newly diagnosed rheumatoid arthritis pa-
tients: A population-based cohort study. Arthritis Rheumatism, 2008; 
58: 2268–2274.
 49.  Lundbegr IE. The heart in dermatomyositis and polymyositis. Rheu-
matology, 2006; 45: 18–21.
 50.  Linos E, Fiorentino D, Lingala B. Atherosclerotic cardiovascular 
disease and ermatomyositis: an analysis of the Nationwide Inpatient 
Sample survey. Arthritis Res Therapy, 2013; 15: 1–5.
 51.  Bergfeldt L. HLAB27-associated cardiac disease. Ann Intern Med, 
1997; 127: 621–629.
 52.  Roldan CA, Chavez J, Wiest PW, Qualls CR, Crawford MH. Aortic root 
disease associated with ankylosing spondylitis. Am Coll Cardiol, 1998; 
32: 1397–1404.
 53.  Brunner F, Kunz A, Weber U, Kissling R. Ankylosing spondylitis and 
heart abnormalities: Do cardiac conduction disorders, valve regurgita-
tion and diastolic dysfunction occur more often in male patients with 
diagnosed ankylosing spondylitis for over 15 years than in the normal 
population? Clin Rheumatol, 2006; 25: 24–29.
 54.  Fardet L. Corticosteroid-induced clinical adverse events: Frequency, 
risk factors and patient’s opinion. Br J Dermato, 2007; 157: 142–148. 
 55.  Nakajima A, Doki K, Homma M et al. Investigation of glucocorticoid-
induced side effects in patients with autoimmune diseases. Yakugaku 
Zasshi, 2009; 129: 445–450.
 56.  Naranjo A, Sokka T, Dezcalzo MA et al. Cardiovascular disease in 
patients with rheumatoid arthritis: results from the QUEST-RA study. 
Arthritis Res Ther, 2008; 10: 1–10.
 57.  Tisseverasinghe A, Bernatsky S, Pineau C. Arterial events in persons 
with dermatomyositis and polymyositis. J Rheumatol, 2009; 36: 1–4.
 58.  Batlouni M. Nonsteroidal anti-inflammatory drugs: cardiovascular, 
cerebrovascular and renal effects. Arq Bras Cardiol, 2010; 94: 556–
–563. 
 59.  Gislason GH, Rasmussen JN, Abildstrom SZ, Schramm TK, Hansen ML. 
Increased mortality and cardiovascular morbidity associated with use 
of nonsteroidal anti-inflammatory drugs in chronic heart failure. Arch 
Intern Med, 2009; 169: 141–149.
 60.  Zhao SZ, Burke T. Cost of heart failure among hypertensive users of 
nonspecific NSAIDs and COX-2–specific inhibitors. Am J Manag Care, 
2002; 8: 414–427.
 61.  Costedoat-Chalumeau N, Hulot JS. Heart conduction disorders related 
to antimalarials toxicity: an analysis of electrocardiograms in 85 pa-
tients treated with hydroxychloroquine for connective tissue diseases. 
Rheumatology, 2007; 46: 808–810. 
 62.  Nurmohamed MT, van Halm VP, Dijkmans BA. Cardiovascular risk 
profile of antirheumatic agents in patients with osteoarthritis and 
rheumatoid arthritis. Drugs, 2002; 62: 1599–1609.
 63.  Guedira N, Hajjaj-Hassouni N, Srairi JE et al. Third-degree atrioven-
tricular block in a patient under chloroquine therapy. Rev Rhum Engl 
Ed, 1998; 65: 58–62.
 64.  Veinot JP, Mai KT, Zarychanski R. Chloroquine related cardiac toxicity. 
J Rheumatol, 1998; 25: 1221–1225.
 65.  Costedoat-Chalumeau N, Hulot JS, Amoura Z. Cardiomyopathy related 
to antimalarial therapy with illustrative case report. Cardiology, 2007; 
107: 73–80.
 66.  Fragasso G, Sanvito F, Baratto F. Cardiotoxicity after low-dose chloro-
quine antimalarial therapy. Heart Vess, 2009; 24: 385–387. 
 67.  Salliot C, van der Heijde D. Long-term safety of methotrexate mo-
notherapy in patients with rheumatoid arthritis: A systematic literatu-
re research. Ann Rheum Dis, 2009; 68: 1100–1104. 
 68.  Curtis JR, Kramer J, Martin M et al. Heart failure among younger rheu-
matoid arthritis and Crohn’s patients exposed to TNF-a antagonists. 
Rheumatology, 2007; 46: 1688–1693.
 69.  Piot Ch, Croisille P, Staat P. Effect of cyclosporine on reperfusion injury 
in acute myocardial infarction. N Engl J Med, 2008; 359: 473–481.
 70.  Mewton N, Croisille P, Gahide G et al. Effect of cyclosporine on left 
ventricular remodeling after reperfused myocardial infarction. J Am 
Coll Cardiol, 2010; 55: 1200–1205.
 71.  Grizzard JD, Biondi-Zoccai G. Interleukin-1 blockade with anakinra to 
prevent adverse cardiac remodeling after acute myocardial infarction 
(Virginia Commonwealth University Anakinra Remodeling Trial). Am 
J Cardiol, 2010; 105: 1371–1377. 
